For example, HMGA2 promotes cisplatin resistance in CRC and CC [69, 70] and oxaliplatin resistance in CRC [71]; ABCB1 promotes erastin, docetaxel, and paclitaxel resistance in OC [72, 73]; ITGA2 promotes paclitaxel resistance in OC [74]; WNT10B promotes doxorubicin resistance in TNBC [75] and cisplatin resistance in CRC [76]; and CCNE1 promotes platinum resistance in epithelial ovarian cancer, ovarian cancer, and endometrial cancer [77, 78]. Here, ITGA2 is linked to ovarian carcinoma.